{
    "clinical_study": {
        "@rank": "136055", 
        "arm_group": [
            {
                "arm_group_label": "Kovacaine Mist", 
                "arm_group_type": "Experimental", 
                "description": "Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the efficacy of Kovacaine Mist, and Placebo for\n      inducing pulpal anesthesia of the maxillary teeth in adults."
        }, 
        "brief_title": "Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Anesthesia", 
        "detailed_description": {
            "textblock": "The study will employ a multi-center, randomized, double-blind, placebo-controlled,\n      parallel-groups design to assess the safety and efficacy of Kovacaine Mist delivered\n      intranasally for inducing pulpal anesthesia of maxillary teeth numbers 4 to 13 (maxillary\n      right second premolar to maxillary left second premolar) sufficient to allow completion of\n      the Study Dental Procedure.  The maxillary teeth will be categorized in two subsets,\n      anteriors (teeth numbers 6 to 11) and premolars (teeth numbers 4, 5, 12 and 13).\n\n      The intent is to treat 150 subjects at 3 study sites, 2:1 randomization within each study\n      site, and an overall goal of 100 subjects treated with Kovacaine Mist and 50 treated with\n      placebo. Recruitment will be from diverse dental patient populations with at least 25% of\n      subjects over 50 years of age.  Randomization will be within strata defined by age (\u226450 and\n      >50 years)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 18 years of age or older.\n\n          -  Need for an operative restorative dental procedure requiring local anesthesia for a\n             single vital maxillary tooth (anterior or premolar tooth #4 to #13) with no evidence\n             of pulpal pathology.\n\n          -  Normal lip, nose, eyelid, and cheek sensation.\n\n          -  Able to understand and sign the study informed consent document, communicate with the\n             Investigators, and understand and comply with the requirements of the protocol.\n\n          -  Patency of the naris ipsilateral to the tooth undergoing the Study Dental Procedure\n             (the treatment tooth).\n\n          -  Resting heart rate (HR) between 55 and 100 beats per minute (bpm), inclusive.\n\n          -  Seated systolic blood pressure (SBP) between 95 and 150 mm Hg, inclusive, and seated\n             diastolic blood pressure (DBP) between 60 and 100 mm Hg, inclusive.\n\n        Exclusion Criteria:\n\n          -  Inadequately controlled hypertension (blood pressure greater than 150/100 mm Hg).\n\n          -  Inadequately controlled active thyroid disease of any type.\n\n          -  Frequent nose bleeds (\u2265 5 per month).\n\n          -  Having received dental care requiring a local anesthetic within the 24 hours\n             preceding study entry.\n\n          -  History of allergy to or intolerance of tetracaine, benzyl alcohol, other ester local\n             anesthetics, or para-aminobenzoic acid (as found in PABA-containing sunscreen).\n\n          -  History of allergy or hypersensitivity to articaine, oxymetazoline, epinephrine, or\n             sulfite preservatives.\n\n          -  Use of a monoamine oxidase inhibitor within the 3 weeks preceding study entry.\n\n          -  Nursing, pregnant, suspected of being pregnant, or trying to become pregnant.\n             (Females of child-bearing potential will be required to take a urine pregnancy test\n             on the day of, but prior to, study drug administration to rule out pregnancy.)\n\n          -  Having received any investigational drug and/or participation in any clinical trial\n             within the 30 days prior to study participation.\n\n          -  History of congenital or idiopathic methemoglobinemia."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745380", 
            "org_study_id": "SR 3-03"
        }, 
        "intervention": [
            {
                "arm_group_label": "Kovacaine Mist", 
                "intervention_name": "Tetracaine HCl 3% and Oxymetazoline HCl 0.05%", 
                "intervention_type": "Drug", 
                "other_name": "Kovacaine Mist"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetracaine", 
                "Oxymetazoline", 
                "Phenylephrine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "operative", 
            "dental procedure"
        ], 
        "lastchanged_date": "September 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Loma Linda", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92350"
                    }, 
                    "name": "Center for Dental Research Loma Linda University School"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20740"
                    }, 
                    "name": "University of Maryland, Baltimore"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Pennsylvania, School of Dental Medicine"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Placebo for Anesthetizing Maxillary Teeth in Adults", 
        "other_outcome": {
            "measure": "Completion of the Study Dental Procedure without need for rescue by injection of local anesthetic (yes/no) when three intranasal sprays are used.", 
            "safety_issue": "No", 
            "time_frame": "at 25 minutes, +3 minute window"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Completion of the Study Dental Procedure without need for rescue by injection of local anesthetic (yes/no) when two intranasal sprays are used.", 
            "safety_issue": "No", 
            "time_frame": "at 15 minutes, +3 minute window"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745380"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Completion of the Study Dental Procedure without need for rescue by injection of local anesthetic (yes/no) by age group (\u226450 and >50 years)", 
                "safety_issue": "No", 
                "time_frame": "at 15 minutes (+3 minute window) or 25 minutes (+3 minute window) if third intranasal spray is used"
            }, 
            {
                "measure": "Heart Rate higher than 125 bpm", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Heart Rate lower than 50 bpm", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Increase from baseline in Systolic blood pressure greater than or equal to 25 mm Hg and/or to a value higher than 160 mm Hg", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following drug administration"
            }, 
            {
                "measure": "Decrease from baseline in Systolic blood pressure greater than or equal to 15 mm Hg and/or to a value lower than 90 mm Hg", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following study drug administration"
            }, 
            {
                "measure": "Increase from baseline in Diastolic blood pressure greater than or equal to 15 mm Hg and/or to a value higher than 105 mm Hg", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following study drug administration"
            }, 
            {
                "measure": "Decrease from baseline in Diastolic blood pressure greater than or equal to 10 mm Hg and/or to a value lower than 50 mm Hg", 
                "safety_issue": "Yes", 
                "time_frame": "at any time within 120 minutes following study drug administration"
            }, 
            {
                "measure": "Maximum change from baseline in Heart Rate, Systolic blood pressure and Diastolic blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "from baseline to 120 minutes following drug administration"
            }, 
            {
                "measure": "The profile over time of Heart Rate, Systolic blood pressure and Diastolic blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "from baseline to 120 minutes following drug administration"
            }, 
            {
                "measure": "Alcohol Sniff Test", 
                "safety_issue": "Yes", 
                "time_frame": "administered at approximately 24 hours after drug administration"
            }
        ], 
        "source": "St. Renatus, LLC", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Triligent International", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Tegra Analytics", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "St. Renatus, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}